Prof Petrylak and his colleagues from other US cancer centres recruited 50 patients to the phase I clinical trial. The patients had the most advanced form of prostate cancer, which had spread to the bone and other organs; they had failed hormone therapy and had received up to two previous chemotherapies. The researchers treated them with doses of PSMA ADC at levels ranging from 0.4 to 2.8 mg/kg, by intravenous infusion, over a period of three weeks per cycle, and for up to four treatment cycles.
The researchers detected anti-tumour activity among the patients who were treated at the higher doses. About half of the patients who received doses of 1.8 mg/kg or more showed either a 50% or more reduction in PSA levels, or a fall in CTC in the blood to less than five cells per 7.5 ml of blood, or both.
Anybody know how the results compare to MDVN drug?
The superiority of enzalutamide over placebo was shown with respect to all secondary end points: the proportion of patients with a reduction in the prostate-specific antigen (PSA) level by 50% or more (54% vs. 2%, P
From ph1/2 of enzalutamide, 37% had CTC conversion from favorable to unfavorable.
For JnJs abiraterone ph3, 34-41% had CTC conversion from favorable to unfavorable, while 36-51% had psa decline 50% at week 12.
Based on placebo arm of enzalutamide ph3, it does look like PGNX's anti-PSMA ADC is demonstrating activity. It would be good to see the tables presented in the EORTC conference.